Mark Deeg

EVP, Clinical Development at Cullgen

About

Dr. Deeg has over 25 years of experience in translational medicine and drug development. After obtaining his MD, PhD at the University of Minnesota, he completed his Internal Medicine residency and post-doctoral training at Case Western Reserve University followed by an Endocrinology Fellowship at the University of Washington. A Fellow of the National Lipid Association, he spent over 10 years at Indiana University before joining Eli Lilly as a clinical research physician. At Eli Lilly, he conducted early phase clinical trials and oversaw the biomarker strategy for Lilly’s endocrine portfolio. He later served as the Chief Medical Officer for The Chorus Group; Lilly’s semiautonomous group for innovative research specializing in rapid clinical development programs leading to proof-of-concept. In 2017, he joined Regulus Therapeutics as the Chief Medical Officer where he oversaw all aspects of clinical development. In 2019, he joined Pear Therapeutics as the Vice President of Research and Development overseeing the clinical development of their digital products. His experience includes a wide variety of therapeutic areas including renal disease, diabetes and metabolism, oncology, pain, dermatology, men’s health, psychiatric diseases, addiction, and orphan diseases utilizing a wide range of approaches including small and large molecules, oligonucleotides, and digital therapeutics.

Links

Timeline

  • EVP, Clinical Development

    June, 2021 - present

View in org chart